Long-Term Chelation Therapy with Deferasirox: Effects on Cardiac Iron Overload Measured by T2* MRI

Author： >   Borsellino Zelia   Cuccia Liana   >   Gagliardotto Francesco   Tarantino Rossana  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.4, 2010-04, pp. : 267-273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

By Cappellini MD   Taher A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2391-2402

Informa Healthcare

Access to resources Recommend Favorite

Deferasirox dominates deferoxamine for iron overload

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 665, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Deferasirox a strong contender for iron overload in all ages

By  

Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload

By  

Current Pharmaceutical Design, Vol. 12, Iss. 16, 2006-06 ,pp. : 1943-1947

Bentham Science Publishers

Access to resources Recommend Favorite

Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite